58.95 USD
-1.4 (-2.32%)
59.28 USD
+0.33 (+0.56%)
We assign a fundamental rating of 6 out of 10 to BMRN. BMRN was compared to 528 industry peers in the Biotechnology industry. BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. BMRN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, BMRN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year BMRN was profitable.
BMRN had a positive operating cash flow in the past year.
BMRN had positive earnings in 4 of the past 5 years.
BMRN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BMRN has a Return On Assets of 6.83%. This is amongst the best in the industry. BMRN outperforms 92.64% of its industry peers.
With an excellent Return On Equity value of 8.59%, BMRN belongs to the best of the industry, outperforming 92.08% of the companies in the same industry.
The Return On Invested Capital of BMRN (7.69%) is better than 93.96% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 18.28%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN has a Profit Margin of 16.82%. This is amongst the best in the industry. BMRN outperforms 92.64% of its industry peers.
BMRN has a better Operating Margin (20.21%) than 94.53% of its industry peers.
With an excellent Gross Margin value of 81.32%, BMRN belongs to the best of the industry, outperforming 85.28% of the companies in the same industry.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
The number of shares outstanding for BMRN has been increased compared to 5 years ago.
BMRN has a better debt/assets ratio than last year.
2.2 Solvency
BMRN has an Altman-Z score of 5.56. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
BMRN has a Altman-Z score of 5.56. This is in the better half of the industry: BMRN outperforms 73.77% of its industry peers.
The Debt to FCF ratio of BMRN is 0.72, which is an excellent value as it means it would take BMRN, only 0.72 years of fcf income to pay off all of its debts.
BMRN's Debt to FCF ratio of 0.72 is amongst the best of the industry. BMRN outperforms 94.53% of its industry peers.
BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BMRN (0.10) is worse than 62.45% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.56 |
ROIC/WACC0.92
WACC8.32%
2.3 Liquidity
BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Current ratio of 4.83. This is comparable to the rest of the industry: BMRN outperforms 55.85% of its industry peers.
BMRN has a Quick Ratio of 3.10. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BMRN (3.10) is worse than 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.00% over the past year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.39%.
The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.19% on average per year.
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.22% yearly.
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y28.19%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.22%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BMRN is valuated rather expensively with a Price/Earnings ratio of 22.16.
94.53% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (27.19), we can say BMRN is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 13.08, the valuation of BMRN can be described as correct.
Based on the Price/Forward Earnings ratio, BMRN is valued cheaply inside the industry as 97.17% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.92, BMRN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.16 | ||
| Fwd PE | 13.08 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaply inside the industry as 94.91% of the companies are valued more expensively.
97.36% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.71 | ||
| EV/EBITDA | 14.43 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 35.49% in the coming years.
PEG (NY)0.62
PEG (5Y)N/A
EPS Next 2Y42.79%
EPS Next 3Y35.49%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
58.95
-1.4 (-2.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.82%
Inst Owner Change0.76%
Ins Owners0.64%
Ins Owner Change-0.62%
Market Cap11.32B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target92.08 (56.2%)
Short Float %4.25%
Short Ratio2.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-0.96%
PT rev (3m)-5.43%
EPS NQ rev (1m)-3.95%
EPS NQ rev (3m)8.36%
EPS NY rev (1m)1.38%
EPS NY rev (3m)-14.9%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.16 | ||
| Fwd PE | 13.08 | ||
| P/S | 3.66 | ||
| P/FCF | 13.71 | ||
| P/OCF | 12.39 | ||
| P/B | 1.87 | ||
| P/tB | 2.01 | ||
| EV/EBITDA | 14.43 |
EPS(TTM)2.66
EY4.51%
EPS(NY)4.51
Fwd EY7.64%
FCF(TTM)4.3
FCFY7.29%
OCF(TTM)4.76
OCFY8.07%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.62
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.56 |
F-Score8
WACC8.32%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.07%
EBIT Next 3Y41.21%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 35.7% in the next year.